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80 Poster Session-I0,833 6 0,155 g/cm2 in the second evaluation (p\0,01). The mean
reduction of the BMD was -1.7 6 9.2% in the LS and -1.7 6
3.3% in the WB. Fourteen (35%) patients had a reduction greater
than 5% in LS, 9 (64%) of them were submitted to unrelated allo-
genic HCT, and 10 (71%) developed Graft Versus Host Disease
(GVHD). Nine patients (13%) had a reduction greater than 5% in
lean body mass. Fifteen patients (38%) had insufficient calcium in-
take in the first evaluation and 20 patients (50%) in the second eval-
uation. Seven patients (18%) had insufficient vitamin D intake in the
first evaluation and 12 patients (30%) in the second evaluation. We
found a positive correlation between changes in BMD in the whole
body and changes in body weight (r 5 0,38; p\0,01).
Conclusion: The prevalence of BMD and lean body mass reduc-
tion was high after six months ofHSCT.There was an important de-
crease in the calcium and vitaminD intake. Children and adolescents
undergoing HCT need nutritional intervention and we suggest
a routine BMD evaluation in those who are at risk for reduction in
bone mass.217
A POPULATION-BASED SINGLE INSTITUTION EVALUATION OF 16 YEARS
OF ALLOGENEIC HSCT IN CHILDHOOD ALL
Ifversen, M.1, Muller, K.1, Jacobsen, N.2, Baekgaard, H.1, Heilmann, C.1
1Rigshospitalet, Copenhagen, Denmark; 2Rigshospitalet, Copenhagen,
Denmark
ALL remains one of the most important causes of haematopoietic
stem cell transplantation (HSCT) in children. The outcome of the
procedure depends on several factors e.g.: 1) ALL subtype 2) pre
transplant treatment 3) leukaemia stage at transplantation 4) condi-
tioning regimen and GvH prophylaxis 5) donor selection and 6)
quality of supportive treatment. In a retrospective analysis of popu-
lation-based data prospectively collected we made an attempt to an-
alyse these factors in a Danish context.
Patients:The course of 85 children\18 years diagnosed between
1–1 1992 and Oct 2008 was examined. This cohort constituted all
children with ALL transplanted in Denmark in this period. All pa-
tients were transplanted at the same centre. Forty-five patients re-
ceived first line treatment according to the Nordic NOPHO1992
protocol and 40 patients according to the NOPHO2000 protocol.
Results: A significant improved survival was recorded between
patients pre-treated according to the NOPHO1992 (KM 5y sur-
vival: 51%) and the later NOPHO2000 protocol (KM 5y survival:
70%). Since the overall survival results for the two treatment pro-
tocols are essentially the same the difference in transplant outcome
is supposed to be due to transplant related causes. An analysis of the
causes for this difference showed that predominantly TRM has de-
clined in the later period but the risk for relapse also decreased. The
survival chance of children transplanted with an HLA-id Sib donor
was particularly good with a KM 5y-survival of around 80%.
The survival of patients transplanted with an UD had a KM 5y-
survival of around 60%. Among factors that were found to be
important for the improved survival were the inclusion of etoposide
in the conditioning regimen and the exclusion of MTX for GvH
prophylaxis.
Conclusion: Significant improvement in survival of ALL children
afterHSCThas occurred within the past 16 years. It is presumed that
during recent years patients in need of an HSCT are not in a better
general condition than earlier and do not have a less aggressive dis-
ease. Never the less as well an improvement in TRM as in the risk of
relapse explain the overall improvement in survival.218
REDUCTION OF TREATMENT RELATED MORTALITY AFTER STEM CELL
TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH ALL UN-
DERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: THE VALUE
OF SEVERE ADVERSE EVENT REPORTING
Schrauder, A.1, Schrappe, M.1, Stackelberg, A.2, Bader, P.3, Peters, C.4
1University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;
2Charite - Medical University, Berlin, Germany; 3Johann Wolfgang
Goethe University, Frankfurt, Germany; 4St. Anna Children’s Hospital,
Vienna, AustriaAlthough allogeneic stem cell transplantation (alloSCT) effec-
tively prevents relapse of acute lymphoblastic leukemia (ALL), trans-
plant related mortality (TRM) may counterbalance that beneficial
effect. In 2003 the BFMStudyGroup initiated a prospective interna-
tional multicenter trial. aiming to standardize and harmonize the
SCT procedure in order to minimize risk of TRM. The immediate
reporting of severe adverse events (SAE) is mandatory in this ongo-
ing study and the findings are regularly discussed within study com-
mittee meetings. Here we report on the frequency, incidence and
outcome of SAE’s in study protocol patients who underwent al-
loSCT between September 2003 and June 2008. 262 children and
adolescents with ALL were recruited by 27 participating SCT cen-
ters. Indications for SCT were all high risk leukemia in any remis-
sion. Conditioning regimen was TBI1VP16 for SCT from MSD
(matched sibling donor), TBI1VP161ATG for SCT from MD
(matched donor), and TBI1Flu1VP161ATG for SCT from
MMD (mismatched donor).
Results: Ninetyone forms reported on life threatening, fatal or
unanticipated problems. Most common reported events were acute
respiratory distress syndromes, disseminated viral infections , bac-
terial sepsis and acute GVHD grade III and IV. Veno-occlusive
disease and other life threatening toxicities were rare events.The
day 360-TRM was 5% in the MSD-group, 4% in the MD-group
and 25% in the MMD group. Overall, 25/262 pts died due to treat-
ment related events. Five pts died after MSD-SCT (all had
a MMD-indication): 2 pts experienced multi organ failure (MOF)
due to infections, 2 pts due to severe acute GVHD and 1 pt
because of extensive chronic GVHD. In the MD-group (all were
transplanted from unrelated donors) 11 pts had fatal treatment
associated outcome: 8 infection associated MOF, 1 EBV-
lymphoproliferative disease, 2 cerebral complications of unidenti-
fied origin, 1 severe bleeding). Four/11 pts underwent second SCT
due to primary or secondary graft failure. Six pts died after
MMD-SCT: 2 after a second or third transplant procedure due
to graft failure, all of them were infection-associated (5 viral, 1
Listeria-meningitis). We conclude that the high quality perfor-
mance of participating centers as well as excellent compliance to
the recommended regimen, better diagnostic measures and
(pre-emptive) treatment of infections, and close and prospective
monitoring of all patients may contribute to the reduced TRM
after alloSCT in children with ALL.219
PREVALENCE, RISK FACTORS AND MANAGEMENT OF METABOLIC SYN-
DROME AFTER STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS
Soni, S.1, Termuhlen, A.1, Bajwa, R.P.S.1, Clayton, J.1,
Montgomery, M.2, Hardin, D.2 1Nationwide Children’s Hospital, Colum-
bus, OH; 2Nationwide Children’s Hospital, Columbus, OH
Background: Metabolic syndrome (MS) is reported to be highly
prevalent in survivors of cancer and allogeneic stem cell transplant
(SCT). TBI, chemotherapy, GVHD and it’s treatment have been
implicated as factors leading to MS after allogeneic SCT.We report
preliminary results of the study which is being done with the objec-
tives 1) to estimate the prevalence ofMS in children followed at a sin-
gle US institution; 2) to analyze risk factors associated with the
development ofMS; and 3) to correlateMSwith other endocrine dis-
orders post-SCT.
Methods: All patients in the follow-up clinic (.1 year post-SCT)
are screened for lipid profile, BP, BMI, waste-hip ratio, microalbu-
minuria. Diagnosis of MS is based on NCEP-ATPIII criteria.
Once diagnosed, patients are retrospectively analyzed regarding de-
mographics, type of SCT, pre-transplant BMI, occurrence and treat-
ment of GVHD, associated endocrine issues. Patients are educated ,
placed on statins and liver function monitored periodically.
Results: 32 patients have been screened till date and 11 (34.3%)
diagnosed with MS. The median age is 15 years (11–20 years); 6 fe-
male and 5 male. The median duration from SCT to diagnosis was
7.5 years (2.5–14.7 yrs). 7 patients received an allogeneic and 4 an au-
tologous SCTwith varied preparative regimens. Themedian BMI at
the time of diagnosis was 22.74 (20.5–36.6). Only 3 (27%) patients
were overweight (BMI. 25) at the time of SCT; there was an aver-
age BMI increase of 5.5 (0.98–9.4) in the interim between SCT and
diagnosis. Hypertriglyceridemia and hypertension were the most
Poster Session-I 81common signs of MS. 2 patients have developed overt diabetes and
are on insulin. Only 2 patients had history of GVHD treated with
steroids. No single factor could be associated with the risk of devel-
oping MS, though the number of cases is too small to do risk-factor
analysis. 2 patients also had GH deficiency. After diet modification
and exercise advise, 7 patients have been placed on Statins and except
for 1, all have tolerated it well with no liver dysfunction noted till
date (median treatment duration :12 months, range 3–23 months).
Conclusions: MS is highly prevalent in pediatric population post
-SCT. Both allogeneic and autologous SCT recipients are suscepti-
ble andMS is not restricted only to overweight recipients.MS should
be suspected, recognized and treated early, as it is a preventable cause
of cardio-vascular morbidity and mortality post-SCT.220
TACROLIMUS AND ‘‘MINI’’ METHOTREXATE IS AN EFFECTIVE REGIMEN
FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE IN CHILDREN UN-
DERGOING UMBILICAL CORD BLOOD TRANSPLANT
Kelly, S.S.1, Kelly, P.2, Hunger, S.P.3, Wingard, J.R.2 1University of
Florida, Gainesville, FL; 2University of Florida, Gainesville, FL; 3The
University of Colorado Denver School of Medicine and The Children’s Hos-
pital, Aurora, CO
Historically, unrelated donor umbilical cord blood transplants
(UCBT) utilized corticosteroids and cyclosporine for graft-versus-
host disease (GVHD) prophylaxis. This combination is associated
with numerous complications including hyperglycemia, hyperten-
sion, avascular necrosis/osteoporosis, and significant infection risk.
Tacrolimus (FK506) and short-course methorexate (MTX) are
used widely for GVHD prophylaxis in adults undergoing hemato-
poietic stem cell transplant. Physicians have been reluctant to use ta-
crolimus/MTX for GVHD prophylaxis following UCBT due to
concerns over the potential for delayed engraftment and increased
mucositis. We report the University of Florida experience with the
combination of ‘‘mini’’ MTX and tacrolimus for GVHDprophylaxis
in children undergoing UCBT. Thirty-one children (ages four
months to 17 years) underwent UCBT between June 2004 and Sep-
tember 2007. Twenty-seven received cord blood from unrelated do-
nors and four from sibling donors. Units were matched with
transplant recipient at 6/6 (n 5 9), 5/6 (n5 11), or 4/6 (n5 11) hu-
man leukocyte antigen loci. Tacrolimus was started as a continuous
infusion at day -3, and changed to twice daily oral dosing when tol-
erated. All children were scheduled to receiveMTX 5mg/m2 on days
1, 3, 6 and 11 followed by lecovorin rescue. Tacrolimus was tapered
beginning between 100 and 180 days post transplant. Twenty-five of
29 eligible patients engrafted, with neutrophil engraftment (ANC.
500) occurring at a median of 18 (range 14–37) days post transplant.
Platelets were greater than 50,000/mm3 untransfused at a median of
42 days post transplant. Recovery of all cell lines occurred earlier
than in historical controls receiving cyclosporine and steroids.
Only one case of grade III or IV acute GVHDwas seen, and no cases
of extensive chronic GVHD. The severity of mucositis was very sim-
ilar to that observed with other GVHD prophylaxis regimens.
Transplant related mortality and infectious complications were as
expected or lower, with twenty children (65%) surviving event free
for a median of 24 (range 8- 45) months post transplant, (overall sur-
vival of 68%). Tacrolimus and ‘‘mini’’MTXwas a well-tolerated reg-
imen for GVHD prophylaxis in pediatric patients undergoing
UCBT. Engraftment kinetics, GVHD occurrence, survival and ad-
verse events compare favorably with historical data for other
GVHD prophylaxis regimens, making this an attractive option for
GVHD prophylaxis in pediatric UCBT.221
SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)— AN OPTION TO
CONSIDER
Duerst, R.E., Jacobsohn, D., Chaudhury, S., Schneiderman, J., Tse,W.T.,
Kletzel, M. Children’s Memorial Hospital and Feinberg School of Medi-
cine, Northwestern University, Chicago, IL
Relapse of ALL following allogeneic HSCT has had an extremely
poor prognosis. Although repeat allogeneic HSCT can be consid-ered, re-treatment with a second full intensity, myeloablative condi-
tioning (MAC) regimen results in significant non-relapse mortality
(NRM) as well as frequent relapse with\20% relapse-free-survival.
Our experience utilizing reduced intensity conditioning (RIC) for
repeat HSCT following prior MACHSCT or MACHSCT follow-
ing prior RIC HSCT for patients (pts) with ALL indicates repeat
HSCT can still lead to cure. We have treated 11 ALL pts with $2
allogeneic HSCT. Seven pts underwent RIC HSCT following at
least one prior MAC HSCT. Similarly, 4 pts who were first treated
with RIC HSCT subsequently underwent a MAC HSCT. The
RIC regimen was comprised of fludarabine, IV busulfan 2 days
and ATG. The MAC regimen was comprised of fTBI, etoposide
and cyclophosphamide. First HSCT donors were matched sibs for
8 pts. The donors for HSCT #2 were different for 8 pts whereas
the same matched sib donated twice for 3 pts. Ten of 11 used
PBSC forHSCT#2.Graft-versus-host disease (GVHD) prophylaxis
was cyclosporin A (CsA)6mycophenolate for RIC HSCT. GVHD
prophylaxis for the MAC #2 pts was tacrolimus-methotrexate-ATG
in 1, CsA alone in 1 and 2 pts received noGVHDprophylaxis. All pts
engrafted. Only one RICHSCT pt succumbed to NRM (pulmonary
failure, having received 2 prior HSCT, one with fTBI and a second
with 4 days of busulfan). Further relapse developed in 3 RIC pts, 2
have died of disease progression, the third pt is in CR, presently
off therapy. One of 4 pts undergoing MAC for HSCT #2 has re-
lapsed and is similarly, in CR, presently off therapy. Three EFS de-
veloped chronic GVHD, 3 did not. The disease-free interval
following HSCT #2 has exceeded that following HSCT #1 for 5
of 11 pts. Kaplan-Meier estimate of OS and EFS at 2-yrs are 72
and 50%, respectively.
Second HSCT for ALL
Age Time (med,
Conditioning
for Second
HSCTGender
M–F(yrs,
median,
range)mo) from
HSCT #1
to HSCT #2EFS (med,
mo) after
HSCT #2OS (med,
mo) after
HSCT #2RIC, n 5 7 5 M–2 F 8.9, (2-16) 19 (11-27) 5 (2-84) 30 (2.5-84)
MAC, n 5 4 2 M–2 F 13.4, (10-17) 15 (7-17) 20 (15-25) 22 (15-25)Our results suggest that despite relapse of ALL following an allo-
geneic HSCT, consideration should be given for a second allogeneic
HSCT with use of a different conditioning regimen.222
RELATIONSHIP BETWEEN DAY 0 CYCLOSPORINE LEVEL AND GRAFT-
VERSUS-HOST DISEASE IN PEDIATRIC HSCT
Duncan, C.N., Buonanno, M.R., Lehmann, L.E. Dana-Farber Cancer
Institute, Boston, MA
We investigated the relationship between the trough cyclosporine
(CSA) level on day 0 and the development of graft-versus-host dis-
ease (GVHD) in pediatric HSCT patients. We performed a retro-
spective review of 162 consecutive allogeneic patients who received
GVHD prophylaxis with CSA, corticosteroid, and short-course
methotrexate. We compared the incidence of acute GVHD
(aGVHD) at day 100 and chronic GHVD at 1-year post-HSCT in
patients with subtherapeutic and therapeutic CSA levels on day 0.
CSA was started on day -2 at a dose of 1.5 mg/kg every 12 hours.
Trough levels less than 125mcg/ml were considered subtherapeutic.
The underlying disease, age at transplant, sex, degree of HLA-
matching, and stem cell source were similar between patients with
therapeutic and subtherapeutic CSA levels. The mean CSA level
on day 0 was 98 mcg/ml (median 108.6) and 113 patients (69.8%)
had a subtherapeutic level. There was no significant difference be-
tween the mean CSA levels of patients that received unrelated donor
(114.7) and related donor (99.3) transplants. There was no significant
difference in the incidence of aGVHD or cGVHD between patients
with subtherapeutic (23%, 34.5%) and therapeutic (30.6%, 44.9%)
CSA levels on day 0 in patients that received unrelated donor or re-
lated donor transplants. All patients with subtherapeutic CSA levels
had dose adjustment and the mean CSA level on day 12 was 155.2
mcg/ml (median 146.5). The mean day at which a therapeutic CSA
level was reached for all patients was day 13.5. This institutional
